Volume 28, Issue 2 - Generics and biosimilars

My First Medical Writing

Author: Evguenia Alechine

Abstract

Download the full article

References

1. White JR Jr. A brief history of the development of diabetes medications. Diabetes Spectrum 2014 May; 27(2):82–6.
2. Marin-Penalver JJ, Martin-Timon I, Sevillano-Collantes C, Del Canizo-Gomez FJ. Update on the treatment of type 2 diabetes mellitus. World Journal of Diabetes. 2016; 7:354–95.
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. E.mpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
4. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.
5. Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PLoS One. 2017;12:e0177646.
6. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–82.
7. Pinto LR, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL Efficacy of SGLT2 inhibitors in glycaemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7(Suppl 1):A58.
8. Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017;13:315–21.
9. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol. 2016;4:411–9.
10. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ, Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7:354–95.
11. American Diabetes Association. 3. Foundations of care and comprehensive medical evaluation, Diabetes Care. 2016;39(Suppl 1):S23–35.
12. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.